Health Tech

Find More: Biotech Pharma
Kura Oncology, Kyowa Kirin Submit its Ziftomenib to FDA

Kura Oncology, Inc., and Kyowa Kirin Co., Ltd. announced Kura submitted a New Drug Application (NDA) for ziftomenib, a highly selective, once-daily, oral, investigational menin inhibitor, for the treatment of…

Join Our Community

Join Our Community